ArticleCureus2024
A Case of Post-COVID Mucormycosis in a Diabetic Patient in Pakistan.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pattern-based clinical recognition of diabetes-associatedFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucormycosis is a rare but potentially fatal angioinvasive fungal infection, caused by filamentous molds of the order Mucorales, which primarily affects immunocompromised individuals and is characterized by high mortality rates. Diabetes mellitus (DM) is the most common risk factor for mucormycosis. During the COVID-19 pandemic, the number of cases significantly increased. Mucormycosis may present in several clinical forms, but the most common form is the rhinocerebral form. This case report aims to emphasize the severity of mucormycosis in a patient with uncontrolled DM who recently recovered from COVID-19. Furthermore, this study demonstrates the importance of early diagnosis and proper treatment to prevent fatal progression. A 58-year-old man is presented in our case report; the patient was recently diagnosed with DM and presented to the outpatient department (OPD) with complaints of right eye ptosis and progressively worsening painful vision loss over 10 days. He had been infected with SARS-CoV-2 infection 15 days earlier and was treated at home with systemic corticosteroids and antibiotics. One week after recovery, he experienced spontaneous nasal bleeding, followed by progressive ocular symptoms that culminated in restricted eye movement and complete vision loss in the right eye. Physical examination revealed right eye proptosis and no light perception. Laboratory tests indicated an elevated C-reactive protein (CRP) level of 25.65 mg/dL and a significantly high glycated hemoglobin A1c (HbA1c) level of 16.3%. A tissue biopsy showed inflammatory nasal polyps associated with mucormycosis. The patient was promptly treated with insulin in order to control the elevated HbA1c and amphotericin B to stop the fungal infection and underwent extensive surgical excision. Our case highlights the severity of mucormycosis in a patient with uncontrolled DM who recently recovered from COVID-19 and shedding light on the importance of controlling the DM in order to reduce the negative impacts on the patient's health. The patient underwent proper treatment with antifungals and aggressive surgical excision to prevent more invasion of the fungi. Despite that, neurological deficits persist including complete loss of vision in one eye which reflects the importance of early diagnosis and proper management to prevent fatal progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.